ascendis pharma glp-1 receptor agonist Understanding agonists and their impact on drug discovery GLP-1 Agonists - Endocrinology Advisor
Description
(HKEX: 1672) has unveiled ASC35, a next-generation GLP-1/GIP dual peptide agonist designed for once-monthly subcutaneous dosing in obesity treatment.
The lead study author and doctors share how these unknown side effects can impact your training and the best ways to adjust your workout routine when taking a GLP-1.
To help people figure out who qualifies, whats involved and what to expect for first-time GLP-1 users, a pair of weight management specialists at MUSC Health sat down for this Q&A.
| 228 comments on LinkedIn
Sarah Mess.
See if you qualify for compensation and how to file.
